Zimmer Biomet (NYSE:ZBH) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Zimmer Biomet (NYSE:ZBH) had its target price hoisted by stock analysts at Stifel Nicolaus from $105.00 to $110.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. Stifel Nicolaus’ target price points to a potential upside of 13.18% from the company’s current price.

A number of other research firms have also recently weighed in on ZBH. Citigroup lowered their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Canaccord Genuity Group set a $83.00 price target on Zimmer Biomet in a report on Wednesday, April 29th. Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, July 25th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday. Finally, Weiss Ratings raised Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $102.75.

Zimmer Biomet Stock Performance

ZBH stock traded down $0.97 on Thursday, hitting $97.19. The company had a trading volume of 215,132 shares, compared to its average volume of 2,319,140. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $108.29. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The stock’s 50-day simple moving average is $89.61 and its 200 day simple moving average is $90.02. The stock has a market cap of $18.80 billion, a price-to-earnings ratio of 25.24, a P/E/G ratio of 2.82 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period in the previous year, the business posted $2.07 earnings per share. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities research analysts expect that Zimmer Biomet will post 8.48 earnings per share for the current fiscal year.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.28% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. DV Equities LLC bought a new stake in Zimmer Biomet during the fourth quarter valued at about $25,000. Monetary Solutions Ltd bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $30,000. Gen Wealth Partners Inc bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $31,000. Flagship Harbor Advisors LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $32,000. Finally, Elevation Wealth Partners LLC raised its stake in shares of Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 229 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Quarterly earnings and revenue beat estimates. Zimmer Biomet reported adjusted diluted EPS of $2.07, above the $2.01 analyst consensus, while sales of $2.177 billion exceeded expectations of approximately $2.13 billion. Revenue increased 4.8% year over year, or 4.0% on an organic constant-currency basis. Zimmer Biomet Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised. Management now expects 2026 adjusted EPS of $8.47 to $8.59 and revenue of about $8.6 billion, compared with analyst expectations of $8.48 EPS and $8.5 billion in revenue. The higher sales outlook supports investor confidence in the company’s growth trajectory. Zimmer Biomet raises guidance on Q2 beats
• Positive Sentiment: GAAP profitability improved. Diluted EPS rose 33.8% to $1.03, while adjusted EPS remained stable year over year at $2.07. The earnings beat and raised outlook were the primary catalysts behind the favorable market reaction. Zimmer Biomet Q2 Earnings and Revenues Beat Estimates
• Neutral Sentiment: The guidance increase was modest relative to consensus. The midpoint of the new EPS range is only slightly above current analyst estimates, suggesting investors may continue to focus on execution and the pace of organic growth. Zimmer Biomet Q2 2026 Earnings Call Transcript
• Negative Sentiment: Adjusted margins were under pressure. Despite the earnings beat, profitability faced headwinds, which could limit further upside if cost pressures persist. ZBH’s Q2 Earnings Beat, 2026 View Raised

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.